Great Lakes Advisors LLC Has $9.71 Million Position in ACADIA Pharmaceuticals Inc. $ACAD

Great Lakes Advisors LLC cut its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 42.3% during the 3rd quarter, Holdings Channel reports. The firm owned 454,790 shares of the biopharmaceutical company’s stock after selling 333,245 shares during the quarter. Great Lakes Advisors LLC’s holdings in ACADIA Pharmaceuticals were worth $9,705,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently modified their holdings of the company. Royal Bank of Canada grew its holdings in ACADIA Pharmaceuticals by 74.4% during the first quarter. Royal Bank of Canada now owns 80,528 shares of the biopharmaceutical company’s stock worth $1,338,000 after purchasing an additional 34,352 shares during the period. AQR Capital Management LLC raised its stake in ACADIA Pharmaceuticals by 3.8% in the first quarter. AQR Capital Management LLC now owns 67,672 shares of the biopharmaceutical company’s stock valued at $1,124,000 after buying an additional 2,492 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of ACADIA Pharmaceuticals by 7.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 89,952 shares of the biopharmaceutical company’s stock valued at $1,498,000 after buying an additional 6,303 shares during the last quarter. Empowered Funds LLC bought a new position in shares of ACADIA Pharmaceuticals during the 1st quarter worth approximately $186,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of ACADIA Pharmaceuticals by 14.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 251,056 shares of the biopharmaceutical company’s stock worth $4,170,000 after acquiring an additional 31,931 shares during the last quarter. 96.71% of the stock is owned by institutional investors.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other news, EVP Mark C. Schneyer sold 10,262 shares of the company’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $23.69, for a total transaction of $243,106.78. Following the completion of the sale, the executive vice president directly owned 53,338 shares in the company, valued at approximately $1,263,577.22. This represents a 16.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider James Kihara sold 4,084 shares of the stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $23.69, for a total value of $96,749.96. Following the sale, the insider directly owned 25,058 shares in the company, valued at approximately $593,624.02. This trade represents a 14.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 44,346 shares of company stock valued at $1,010,957 in the last three months. Corporate insiders own 26.50% of the company’s stock.

ACADIA Pharmaceuticals Stock Up 0.3%

Shares of NASDAQ:ACAD opened at $25.70 on Friday. ACADIA Pharmaceuticals Inc. has a 12-month low of $13.40 and a 12-month high of $28.35. The company’s 50 day moving average price is $26.45 and its two-hundred day moving average price is $24.37. The firm has a market cap of $4.35 billion, a PE ratio of 16.58, a PEG ratio of 6.27 and a beta of 0.68.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.28. The business had revenue of $278.63 million during the quarter, compared to analysts’ expectations of $276.52 million. ACADIA Pharmaceuticals had a return on equity of 14.61% and a net margin of 24.94%.The firm’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.20 earnings per share. On average, research analysts expect that ACADIA Pharmaceuticals Inc. will post 0.7 EPS for the current year.

Analysts Set New Price Targets

ACAD has been the subject of several research reports. UBS Group raised their price target on ACADIA Pharmaceuticals from $35.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Weiss Ratings reissued a “hold (c+)” rating on shares of ACADIA Pharmaceuticals in a research report on Monday, December 29th. Citigroup lifted their target price on shares of ACADIA Pharmaceuticals from $33.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Wall Street Zen upgraded shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Sunday, January 11th. Finally, Royal Bank Of Canada cut their price objective on shares of ACADIA Pharmaceuticals from $34.00 to $32.00 and set an “outperform” rating for the company in a research report on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, ACADIA Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $31.16.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.